The program in Radiobiology &Radiotherapy (RR) comprises a broadly based, multifaceted research effort in radiation therapy, radiation biology, radiological physics and related areas of tumor biology. This program has been an approved component of the Yale Cancer Center Grant for over 25 years. Its long-term goal is to improve the treatment of cancer in general and in particular, the effectiveness of radiation therapy. The program includes a broad spectrum of activity that extends from laboratory-based experimental research to clinical investigation, and features investigators associated with 16 departments. Some of the key themes include studies of carcinogenesis, genetic instability and cell growth control;elucidation of DNA repair pathways;investigation of tumor hypoxia and development of hypoxia-targeted cancer therapies;molecular correlations with outcomes in radiation therapy;and improvements in radiation dosimetry, imaging, and delivery. The majority of RR members have rich interactions with the Yale Cancer"""""""" Center (YCC) membership, stimulating translational research that is in turn facilitated by other YCC Research Programs and by extensive use of Shared Resources. The numerous cancer-related grand rounds, seminars, meetings, and journal clubs sponsored by the YCC, along with the weekly Radiobiology Workshop and Journal Club and the weekly Therapeutic Radiology Grand Rounds sponsored by the program, encourage the cooperation, mutual support, and cross stimulation among the component research teams, which leads to a more rapid and efficient application of the results of the research to clinical practice. Dr. Peter Glazer took over as program leader in 2002, replacing Dr. James J. Fischer, who had served as program leader since its inception. In the past funding period, the program expanded to include a total of 39 members affiliated with 15 departments and 3 schools, has played a role in recruiting 3 basic scientists and 6 physician investigators, and has completed renovation of 15,500 net square feet of laboratory space, partially funded by a $2M construction grant from the NIH. Dr. Glazer also serves as PI of a T32 postdoctoral training grant in Radiation Therapy, Biology and Physics, which includes a number of YCC members both within and outside of the program. In the past funding period, there have been 509 cancer related publications by members of the program, including 94 intra- and 121 inter-programmatic collaborations. Overall, the 39 investigators associated with the program have peer-reviewed funding bf $5.8M in annual total costs ($3.7M direct costs), including 17 R01s and an NIH Director's New Innovator Award. Of this funding, $2.3M annual total costs ($1.5M direct costs) comes from the NCI, including 8 ROIs, plus a T32 training grant.
The program in Radiobiology &Radiotherapy seeks to elucidate pathways of cancer biology that impact radiation therapy and to conduct clinical and translational research to improve radiation therapy, a key component in the care of cancer patients.
|Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326|
|Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083|
|Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291|
|Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40|
|Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631|
|Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025|
|Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461|
|Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853|
|Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573|
|Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331|
Showing the most recent 10 out of 675 publications